Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity.

Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA.

Mol Pharm. 2014 Apr 7;11(4):1294-300. doi: 10.1021/mp400760b. Epub 2014 Mar 27.

PMID:
24641451
[PubMed - in process]
2.

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH.

Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27.

PMID:
20663911
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.

Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J, Sonderfan AJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):529-38. doi: 10.1124/jpet.112.196873. Epub 2012 Jul 26.

PMID:
22837008
[PubMed - indexed for MEDLINE]
Free Article
4.

Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Shenoi MM, Iltis I, Choi J, Koonce NA, Metzger GJ, Griffin RJ, Bischof JC.

Mol Pharm. 2013 May 6;10(5):1683-94. doi: 10.1021/mp300505w. Epub 2013 Apr 17.

PMID:
23544801
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.

Crielaard BJ, van der Wal S, Lammers T, Le HT, Hennink WE, Schiffelers RM, Storm G, Fens MH.

Int J Nanomedicine. 2011;6:2697-703. doi: 10.2147/IJN.S24450. Epub 2011 Nov 2.

PMID:
22114500
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM.

J Med Chem. 2001 Nov 22;44(24):4216-24.

PMID:
11708923
[PubMed - indexed for MEDLINE]
7.

Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy.

Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE.

Small. 2014 Feb 12;10(3):566-75, 417. doi: 10.1002/smll.201301456. Epub 2013 Aug 27.

PMID:
24038954
[PubMed - in process]
8.

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT.

J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000.

PMID:
12837835
[PubMed - indexed for MEDLINE]
Free Article
9.

Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.

Vielhauer GA, Swink M, Parelkar NK, Lajiness JP, Wolfe AL, Boger D.

Cancer Biol Ther. 2013 Jun;14(6):527-36. doi: 10.4161/cbt.24348.

PMID:
23760495
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.

Chen KC, Schmuck K, Tietze LF, Roffler SR.

Mol Pharm. 2013 May 6;10(5):1773-82. doi: 10.1021/mp300581u. Epub 2013 Mar 26.

PMID:
23448264
[PubMed - indexed for MEDLINE]
11.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
12.

Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.

Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH.

Cancer Res. 1999 Aug 15;59(16):3998-4003.

PMID:
10463598
[PubMed - indexed for MEDLINE]
Free Article
13.

CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.

Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, Yarranton GT, Buckman D, Roscoe W, Zhou F, Salles A, Chen TH, Horgan K, Wang YH, Nguyen T, Bebbington CR.

Cancer Res. 2003 Sep 1;63(17):5526-31.

PMID:
14500390
[PubMed - indexed for MEDLINE]
Free Article
14.

BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.

Kremmidiotis G, Leske AF, Lavranos TC, Beaumont D, Gasic J, Hall A, O'Callaghan M, Matthews CA, Flynn B.

Mol Cancer Ther. 2010 Jun;9(6):1562-73. doi: 10.1158/1535-7163.MCT-09-0815. Epub 2010 Jun 1.

PMID:
20515948
[PubMed - indexed for MEDLINE]
Free Article
15.

Cardiovascular toxicity profiles of vascular-disrupting agents.

Subbiah IM, Lenihan DJ, Tsimberidou AM.

Oncologist. 2011;16(8):1120-30. doi: 10.1634/theoncologist.2010-0432. Epub 2011 Jul 8.

PMID:
21742963
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).

Biela BH, Khawli LA, Hu P, Epstein AL.

Cancer Biother Radiopharm. 2003 Jun;18(3):339-53.

PMID:
12954121
[PubMed - indexed for MEDLINE]
17.

Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.

Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S.

J Control Release. 2012 Jun 10;160(2):245-53. doi: 10.1016/j.jconrel.2011.11.019. Epub 2011 Nov 26.

PMID:
22134116
[PubMed - indexed for MEDLINE]
18.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
[PubMed - indexed for MEDLINE]
19.

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, Bertolini F, Link DC, Kerbel RS.

Cancer Res. 2009 Oct 1;69(19):7524-8. doi: 10.1158/0008-5472.CAN-09-0381. Epub 2009 Sep 8.

PMID:
19738066
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.

Ravel D, Dubois V, Quinonero J, Meyer-Losic F, Delord J, Rochaix P, Nicolazzi C, Ribes F, Mazerolles C, Assouly E, Vialatte K, Hor I, Kearsey J, Trouet A.

Clin Cancer Res. 2008 Feb 15;14(4):1258-65. doi: 10.1158/1078-0432.CCR-07-1165.

PMID:
18281561
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk